logo
NASA video of moon rocket test shows something just went seriously wrong

NASA video of moon rocket test shows something just went seriously wrong

Yahoo4 days ago
A test of a new rocket motor for NASA's future moon missions went awry this week, with the full-size booster hurling a powerful blaze and scattering debris.
Northrop Grumman, lead contractor for the booster, conducted the two-minute ground test of the solid rocket motor, which was strapped down sideways. For the first 1.5 minutes, the motor — known as NASA's Booster Obsolescence and Life Extension, or BOLE — seemed to be working fine. Seconds later, debris blew out of the nozzle and flames rippled through the long exhaust plume.
The 156-foot booster kept firing through the remainder of the test, and no one was hurt. NASA's livestream, which you can watch below, caught the incident, starting at about 22 minutes and 17 seconds into the video.
Engineers didn't immediately acknowledge the issue during that broadcast, apart from one controller uttering "Whoa," followed by an audible gasp. The company later confirmed a problem occurred late in the burn, though representatives didn't elaborate on what went wrong.
The anomaly, which took place at a Northrop Grumman test facility in Promontory, Utah, raises questions about the hardware that could one day send astronauts into space — and potentially to Mars.
"As a new design, and the largest segmented solid rocket booster ever built, this test provides us with valuable data to iterate our design for future developments," said Jim Kalberer, Northrop Grumman's vice president of propulsion systems, in a statement.
SEE ALSO: Webb telescope smashed a record with the planet it just discovered
A single BOLE booster produces more than 4 million pounds of thrust. Credit: Northrop Grumman
The BOLE motor is a major redesign of the ones used on NASA's Space Launch System, or SLS, the rocket built to carry astronauts to the moon under the Artemis program. It swaps out old parts with lightweight materials and new fuel, giving it more thrust and allowing the rocket to haul heavier loads.
The boosters for the first eight flights of Artemis repurpose the steel booster cases and other parts from the Space Shuttle program. Beginning with Artemis IX, the SLS rocket, sometimes dubbed the mega moon rocket, is supposed to use the BOLE. The plan is for two of them to flank either side of the rocket.
"In order to save cost and schedule, we implemented the Shuttle's proven heritage hardware into our design, but this is being depleted as the Artemis program progresses," said Julia Khodabandeh, NASA's deputy manager for the SLS booster element office. "It's just not practical to restart the manufacturing from that 1970s era."
This was the first demonstration test of the enhanced five-segment solid rocket motor. That single booster produced more than 4 million pounds of thrust, said Dave Reynolds, NASA's SLS booster subsystems manager.
"You can see from the side of the mountain up there," Reynolds said afterward, "it's still feeling the effects of that test."
The purpose of the demonstration was to test the limits of the motor's design, understand the stress and strain on different materials, and see if the motor's components could withstand extreme conditions. The two-minute test mimics the time a booster would fire during a real launch. Northrop Grumman officials said the data from the BOLE test will help improve the design.
The new boosters are not expected to fly until at least the late 2030s, and it's unclear whether they ever will. Proposed budget cuts for NASA would mean SLS production ceases after Artemis III, the first human moon landing since Apollo 17. That mission has been postponed until 2027 at the earliest.
The White House has said it would like to see the space agency focus instead on using commercial systems. Lawmakers are still debating how many more SLS launches, about $4.1 billion each, to fund.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NASA identifies newly discovered object as an interstellar comet that will keep a safe distance
NASA identifies newly discovered object as an interstellar comet that will keep a safe distance

Washington Post

timean hour ago

  • Washington Post

NASA identifies newly discovered object as an interstellar comet that will keep a safe distance

CAPE CANAVERAL, Fla. — NASA has discovered an interstellar comet that's wandered into our backyard. The space agency spotted the quick-moving object with the sky-surveying Atlas telescope in Chile earlier this week, and confirmed it was a comet from another star system. It's officially the third known interstellar object to pass through our solar system and poses no threat to Earth.

NASA identifies newly discovered object as an interstellar comet that will keep a safe distance
NASA identifies newly discovered object as an interstellar comet that will keep a safe distance

San Francisco Chronicle​

timean hour ago

  • San Francisco Chronicle​

NASA identifies newly discovered object as an interstellar comet that will keep a safe distance

CAPE CANAVERAL, Fla. (AP) — NASA has discovered an interstellar comet that's wandered into our backyard. The space agency spotted the quick-moving object with the sky-surveying Atlas telescope in Chile earlier this week, and confirmed it was a comet from another star system. It's officially the third known interstellar object to pass through our solar system and poses no threat to Earth. The newest visitor is 416 million miles (670 million kilometers) from the sun, out near Jupiter. NASA said the comet will make its closest approach to the sun in October, scooting between the orbits of Mars and Earth — but closer to the red planet than us at a safe 150 million miles (240 million kilometers) away. Astronomers around the world are monitoring the comet — an icy snowball officially designated 3I/Atlas — to determine its size and shape. It should be visible by telescopes through September, before it gets too close to the sun, and reappear in December on the other side of the sun. The first interstellar visitor observed from Earth was Oumuamua, Hawaiian for scout, in honor of the observatory in Hawaii that discovered it in 2017. Classified at first as an asteroid, the elongated Oumuamua has since showed signs of being a comet. The second object confirmed to have strayed from another star system into our own —— 21/Borisov — was discovered in 2019 by a Crimean amateur astronomer with that name. It, too, is believed to be a comet. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Sunvozertinib Wins Approval for EGFR-Mutated NSCLC
Sunvozertinib Wins Approval for EGFR-Mutated NSCLC

Medscape

timean hour ago

  • Medscape

Sunvozertinib Wins Approval for EGFR-Mutated NSCLC

The FDA has granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR) exon 20 insertion mutations that's progressed on or after platinum-based chemotherapy. The agency also approved Oncomine Dx Express Test (Life Technologies Corporation) as a companion diagnostic to detect the mutations. The oral EGFR inhibitor is the first small molecule approved in the US for the indication; it was previously approved in China. The intravenous bispecific antibody amivantamab-vmjw (Rybrevant, Johnson & Johnson) also carries a second-line indication for EGFR exon 20 insertion mutated advanced/metastatic NSCLC, as well as a first-line indication with carboplatin and pemetrexed. Dizal is going for a first-line indication, too. The company recently announced completion of enrolment in a phase 3 trial pitting sunvozertinib against platinum-based chemotherapy for the upfront treatment of EGFR exon 20 insertion mutated NSCLC. The new second-line approval was based on WU-KONG1B, a multinational dose finding trial. All subjects had previous platinum-based chemotherapy and 43.4% had also received immunotherapy; 13.3% had been on amivantamab. Among 85 patients on 200 mg sunvozertinib daily, the overall response rate was 46% and the duration of response was 11.1 months. Labelling warns of the possibility of interstitial lung disease/pneumonitis, gastrointestinal adverse reactions, dermatologic issues, ocular toxicity, and embryo-fetal toxicity. Diarrhea, skin rash, and creatine phosphokinase increase were the most common drug-related treatment emergent adverse events in the trial, with most events being grade 1 or 2. The recommended dose is 200 mg orally once daily with food until disease progression or unacceptable toxicity. M. Alexander Otto is a physician assistant with a master's degree in medical science and a journalism degree from Newhouse. He is an award-winning medical journalist who worked for several major news outlets before joining Medscape. Alex is also an MIT Knight Science Journalism fellow. Email: aotto@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store